Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that
accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric …

Approximately two-thirds of children with acute myeloid leukemia (AML) are cured with
intensive multi-agent chemotherapy. However, refractory and relapsed AML remains a …

Pediatric acute myeloid leukemia (AML) is a heterogeneous disease with various genetic
abnormalities. Recent advances in genetic analysis have enabled the identification of …

Acute myeloid leukemia (AML) is a clinically, morphologically, and genetically
heterogeneous disorder. Like many malignancies, the genomic landscape of pediatric AML …

Although the outcome has improved over the past decades, due to improved supportive
care, a better understanding of risk factors, and intensified chemotherapy, pediatric acute …

While acute myeloid leukemia (AML) is significantly less common than acute lymphoblastic
leukemia (ALL) in childhood, it is significantly more deadly with only half as many children …

Acute myeloid leukemia (AML) accounts for approximately 15–20% of all childhood
leukemia cases. The overall survival of children with acute myeloid leukemia does not …

Simple Summary Owing to the 40-year worldwide efforts for improving diagnosis and
therapy for acute myeloid leukemia (AML), the second most common type of leukemia in …

Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and
transcriptional etiology mainly presenting somatic and germline abnormalities. AML …

Further incorporation of genomic and molecular data in pediatric AML will allow for
additional refinements in risk stratification to enable the tailoring of treatment intensity. These …